GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of Arexvy (Respiratory Syncytial Virus Vaccine) when co-administered with Shingrix (Zoster Vaccine).
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
Good signs for co administration of GSK’s RSV and shingles vaccines
UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial showed that co-administering Arexvy (RSV vaccine) and Shingrix (shingles vaccine) in adults 50+ produced a non-inferior immune response and was well tolerated.
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older. The British pharma giant said Wednesday a Phase 3 study evaluating RSV vaccine Arexvy co-administered with Shingrix met the primary endpoint,
GSK posts late-stage trial win for co-administered RSV and shingles vaccines
GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix. Read more here.
GSK's RSV vaccine meets main goal when co-administered with shingles shot
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age.
Gazeta.pl on MSN3d
A Vaccine Against an Infectious Disease Protects Against Dementia? "Intriguing"
The latest research suggests that the recombinant shingles vaccine may offer additional benefits. It appears to reduce the ...
Armed robbery in Revesby18h
More Australians to Get Funded Shingles Vaccine
Melbourne, Australia The Government has expanded access to GSK's shingles vaccine, Shingrix, to cover individuals aged 18 ...
American States Ranked by the Highest and Lowest Vaccination Rates
Rhode Island has the highest vaccination rate across the country, while Mississippi was found to have the lowest, a new study ...
dermatologyadvisor9d
No Increased Risk for Incident Gout After RZV Exposure Among Adults Aged 50 Years or Older
The risk for incident gout following RZV exposure was not increased among adults aged 50 years or older, according to study findings.
GEN12d
Increasing Vaccine Efficacy with Novel Adjuvants
Derived from the Latin adjuvare (to help or aid), adjuvants enhance antigen-specific vaccine immunogenicity. Added only when ...
Want To Lower Your Dementia Risk? Don’t Skip This Vaccine
Additionally, Dr. Brangman says that the Tdap vaccine, which protects against tetanus, diphtheria and whooping cough, is also ...
Joplin Globe4d
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
Please see full Prescribing Information for AREXVY. About SHINGRIX (Recombinant Zoster Vaccine or RZV) SHINGRIX is a non-live, recombinant subunit vaccine indicated for the prevention of ...
Bronx Times-Reporter12dOpinion
Column: Vaccines: A critical step to keep you and your family healthy
Vaccinating yourself and your family against serious transmissible diseases is one of the most important steps you can take ...
More Australians to get free vaccine for shingles
Australians ages 18 to 64 who are classed as "moderate to high risk" will be able to get the shingles jab. ...